The progesterone receptor Val660→Leu polymorphism and breast cancer risk

DSpace/Manakin Repository

The progesterone receptor Val660→Leu polymorphism and breast cancer risk

Show simple item record

dc.contributor.author De Vivo, Immaculata
dc.contributor.author Hankinson, Susan Elizabeth
dc.contributor.author Colditz, Graham A.
dc.contributor.author Hunter, David J.
dc.date.accessioned 2011-04-29T04:32:48Z
dc.date.issued 2004
dc.identifier.citation De Vivo, Immaculata, Susan E. Hankinson, Graham A. Colditz, and David J. Hunter. 2004. The progesterone receptor Val660→Leu polymorphism and breast cancer risk. Breast Cancer Research 6(6): R636-R639. en_US
dc.identifier.issn 1465-5411 en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:4879209
dc.description.abstract Background: Recent evidence suggests a role for progesterone in breast cancer development and tumorigenesis. Progesterone exerts its effect on target cells by interacting with its receptor; thus, genetic variations, which might cause alterations in the biological function in the progesterone receptor (PGR), can potentially contribute to an individual's susceptibility to breast cancer. It has been reported that the PROGINS allele, which is in complete linkage disequilibrium with a missense substitution in exon 4 (G/T, valine→leucine, at codon 660), is associated with a decreased risk for breast cancer. Methods: Using a nested case-control study design within the Nurses' Health Study cohort, we genotyped 1252 cases and 1660 matched controls with the use of the Taqman assay. Results: We did not observe any association of breast cancer risk with carrying the G/T (Val660→Leu) polymorphism (odds ratio 1.10, 95% confidence interval 0.93–1.30). In addition, we did not observe an interaction between this allele and menopausal status and family history of breast cancer as reported previously. Conclusion: Overall, our study does not support an association between the Val660→Leu PROGINS polymorphism and breast cancer risk. en_US
dc.language.iso en_US en_US
dc.publisher BioMed Central en_US
dc.relation.isversionof doi:10.1186/bcr928 en_US
dc.relation.hasversion http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064075/pdf/ en_US
dash.license LAA
dc.subject breast cancer en_US
dc.subject linkage disequilibrium en_US
dc.subject polymorphism en_US
dc.subject progesterone receptor en_US
dc.title The progesterone receptor Val660→Leu polymorphism and breast cancer risk en_US
dc.type Journal Article en_US
dc.description.version Version of Record en_US
dc.relation.journal Breast Cancer Research en_US
dash.depositing.author De Vivo, Immaculata
dc.date.available 2011-04-29T04:32:48Z
dash.affiliation.other SPH^Epidemiology en_US
dash.affiliation.other HMS^Medicine-Brigham and Women's Hospital en_US
dash.affiliation.other SPH^Epidemiology en_US
dash.affiliation.other HMS^Medicine-Brigham and Women's Hospital en_US
dash.affiliation.other SPH^Epidemiology en_US
dash.affiliation.other HMS^Ophthalmology en_US

Files in this item

Files Size Format View
1064075.pdf 106.6Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters